Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




SoftGenetics, LLC.

click to enlarge

Chimerism Software

This new automated chimerism software, ChimerMarker™, integrates analysis operations for initial donor/recipient compatibility and post engraftment longitudinal studies. The new software is compatible with outputs from major capillary electrophoresis platforms as well as commercially available STR and custom chemistries. ChimerMarker software can be used to monitor chimerism in allogeneic and autologous stem cell transplant, hematopoietic stem cell transplant, bone marrow transplant, and peripheral blood stem cell transplant. The program preferences include labeling of peak ratios by height or area, with multilineage capabilities for chimerism analysis of T cells, B cells, and other cell type populations, which may indicate graft-versus-host disease or graft rejection. Case-specific panels are automatically constructed using donor recipient allele calls.

Related To This Company

Products

Related content

Webinars

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll